unproven safety profiles or translational potential. Here we show that an FDA-approved drug with a previously proven record of safety is able to completely inhibit ectopic lesions in a mouse model of FOP carrying the same mutation.
RESULTS:
While mice which received Ad.cre/CTX without rapamycin produced ectopic bone consistently, treatment with rapamycin nearly eliminated HO based on both microCT imaging (34.0 mm 3 v. 1.0 mm 3 , p<0.01). Furthermore, histologic imaging showed elimination of ectopic cartilage with rapamycin treatment based on H&E, pentachrome staining (red arrows) and SOX9 immunofluorescence. Finally, rapamycin reduced the presence of mesenchymal cells (PDGFRa+ or aSMA+) at the injury site. PLGA microparticles released rapamycin during the first week after injury based on flow cytometry analysis. Mice that had resection of HO and were treated with rapamycin did not recur, while 100% of mice which had resection of HO without rapamycin developed new lesions at the resection site.
CONCLUSION: These findings demonstrate that rapamycin, an FDA-approved drug, eliminates ectopic cartilage and bone in a mouse model of FOP. This may occur through a reduction in the presence of activated mesenchymal cells at the injury site. These findings have prompted the initiation of clinical studies to assess efficacy of this potential therapeutic in humans. A slow-release microparticle may obviate repeated treatments in these patients. Rapamycin may also have a role in the management of FOP patients with ossified lesions, making surgical resection a reality for the first time. PURPOSE: Macromastia, the benign overgrowth of one or both breasts, is a common condition with a well-documented negative impact on mental and physical health, self-esteem, and social functioning. Reduction mammaplasty during adolescence is relatively controversial; the psychological effects of treatment in this age group are largely unknown. This study seeks to measure changes in health-related quality-of-life (HRQOL) and breastrelated symptoms following reduction mammaplasty in adolescents, and explore the effects of age and BMI category at time of surgery on postoperative quality-of-life outcomes.
METHODS:
In this longitudinal cohort study, our group administered the Short-Form 36v2 (SF-36), Rosenberg SelfEsteem Scale (RSES), Breast-Related Symptoms Questionnaire (BRSQ), and Eating-Attitudes Test-26 (EAT-26) to 102 adolescents with macromastia and 84 unaffected female controls, aged 12 to 21 years. Patients with macromastia completed surveys preoperatively and postoperatively (at 6 months, 1 year, 3 years, and 5 years). Control subjects completed baseline and follow-up surveys at the same intervals. Higher scores in the SF-36, RSES, and BRSQ are associated with a better HRQOL, global self-esteem, and fewer/less severe breastrelated symptoms, respectively. Higher scores in the EAT-26 are indicative of disordered eating thoughts and behaviors.
RESULTS:
Mean age at the time of reduction mammaplasty was 17.9 ± 1.7 years. Patients with macromastia demonstrated significant score improvements postoperatively from baseline on the RSES, BRSQ, and in seven out of eight SF-36 domains. Postoperative subjects scored significantly higher than controls at follow-up on the RSES and in four SF-36 domains (physical functioning, bodily pain, social functioning, and mental health), when controlling for differences in baseline BMI category (p<0.05, all). Followup scores on the EAT-26, BRSQ, and in four SF-36 domains (role-physical, general health, vitality, and role-emotional) did not differ between the two groups (p≥0.05, all). Following reduction mammaplasty, the proportion of patients experiencing pain, bra strap grooving, inframammary intertrigo, and difficulty participating in sports and finding properly fitting bras/clothing was significantly lower than at baseline (p<0.001, all), with postoperative rates similar to those seen in control subjects (p≥0.05, all). Both younger (<18 years, n=54) and older patients (≥18 years, n=48) had significant postoperative improvements in RSES and BRSQ scores. On the SF-36, only older patients experienced a benefit in the mental health subscale (p<0.001). When the macromastia group was stratified by BMI category, both healthyweighted (n=38) and overweight/obese patients (n=64) had significant postoperative improvements on the RSES and BRSQ, and six SF-36 domains. Unlike their healthyweighted counterparts, overweight/obese patients did not have improvements in SF-36 general health (p=0.65).
CONCLUSION:
Reduction mammaplasty was significantly associated with improvements in HRQOL and breastrelated symptoms of adolescent patients. Postoperatively, patients report levels of well-being similar to, if not higher than, unaffected age-matched females. These results largely do not vary by BMI category or age. Patients and providers should be aware of the potential benefit of reduction mammaplasty for adolescents with symptomatic macromastia.
